Literature DB >> 27642112

Temporal Trends, Predictors, and Outcomes of In-Hospital Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention.

Nileshkumar J Patel1, Dhaval Pau2, Nikhil Nalluri2, Parth Bhatt3, Badal Thakkar4, Ritesh Kanotra5, Kanishk Agnihotri6, Nitesh Ainani6, Nilay Patel6, Nish Patel7, Sapna Shah8, Sabeeda Kadavath9, Shilpkumar Arora10, Azfar Sheikh2, Apurva O Badheka11, James Lafferty2, Carlos Alfonso7, Mauricio Cohen7.   

Abstract

Since the introduction of new antiplatelet and anticoagulant agents in the last decade, large-scale data studying gastrointestinal bleeding (GIB) in patients undergoing percutaneous coronary intervention (PCI) are lacking. Using the Nationwide Inpatient Sample, we identified all hospitalizations from 2006 to 2012 that required PCI. Temporal trends in the incidence and multivariate predictors of GIB associated with PCI were analyzed. A total of 4,376,950 patients underwent PCI in the United States during the study period. The incidence of GIB was 1.1%. Mortality rate in the GIB group was significantly higher (9.71% vs 1.1%, p <0.0001). Although the incidence of GIB remained stable during the study period (0.97% in 2006 to 1.19% in 2012), in-hospital mortality rate increased significantly from 7.9% in 2006 to 10.78% in 2012, with a peak of 12% in 2010. The GIB group had a longer median length of stay (5.80 vs 1.57 days) and an increased median cost of hospitalization ($26,564 vs $16,879). The predictors of GIB included cardiovascular co-morbidities such as acute myocardial infarction, cardiogenic shock, atrial fibrillation, congestive heart failure, valvular heart diseases, and a history of transient ischemic attack/stroke. Gastrointestinal co-morbidities including diverticulosis, esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, rectosigmoid cancer, gastrointestinal ulcer, and liver disease were predictors of GIB. Interestingly, a lower risk of GIB was associated with obese patients and patients with private insurance. A higher risk of GIB was noted in urgent versus elective admissions and weekend versus weekday admissions. In conclusion, the incidence of GIB in patients who underwent PCI remained stable from 2006 to 2012; however, the in-hospital mortality increased significantly. Identifying patients at higher risk for GIB is critically important to develop preventive strategies to reduce morbidity and mortality.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27642112     DOI: 10.1016/j.amjcard.2016.07.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Incidence, Predictors, and Outcomes of Gastrointestinal Bleeding in Patients Admitted With ST-Elevation Myocardial Infarction.

Authors:  Ridwaan Albeiruti; Fahad Chaudhary; Fahad Alqahtani; Justin Kupec; Sudarshan Balla; Mohamad Alkhouli
Journal:  Am J Cardiol       Date:  2019-05-15       Impact factor: 2.778

2.  Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.

Authors:  Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice
Journal:  Eur Heart J       Date:  2019-08-14       Impact factor: 29.983

Review 3.  Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice
Journal:  Circulation       Date:  2019-05-22       Impact factor: 29.690

4.  Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Anping Cai; Chrisly Dillon; William B Hillegass; Mark Beasley; Brigitta C Brott; Vera A Bittner; Gilbert J Perry; Ganesh V Halade; Sumanth D Prabhu; Nita A Limdi
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

5.  Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer: A Nationwide Registry-Based Study.

Authors:  Jan Walter Dhillon Shanmuganathan; Kristian Kragholm; Bhupendar Tayal; Christoffer Polcwiartek; Laurids Østergaard Poulsen; Tarec Christoffer El-Galaly; Emil Loldrup Fosbøl; Maria D'Souza; Gunnar Gislason; Lars Køber; Morten Schou; Dorte Nielsen; Peter Søgaard; Christian Tobias Torp-Pedersen; Mamas A Mamas; Phillip Freeman
Journal:  JACC CardioOncol       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.